Advertising in the International Journal of Keratoconus and Ectatic Corneal Diseases: A Practical Guide to IJKECD Magazine Advertising, Ad Rates, and Reaching India's Corneal Disease Specialists

Most pharmaceutical and medical device brands underestimate how precisely a specialist peer-reviewed journal can deliver their message — and the International Journal of Keratoconus and Ectatic Corneal Diseases is one of the clearest examples of that precision at work in Indian ophthalmology. The corneal disease segment is growing faster than the broader eye care market, which means the window for early-mover brand positioning in this space is narrowing. At SmartAds, we have worked with healthcare and pharma clients who were spending significant budgets on broad ophthalmology outreach while missing the one publication that their exact target prescriber was actually reading.

What Is the International Journal of Keratoconus and Ectatic Corneal Diseases?

There is a reason this journal has quietly built one of the most loyal specialist readerships in Indian ophthalmology — it does not try to be everything to everyone. The International Journal of Keratoconus and Ectatic Corneal Diseases, published under the ISSN 2277-3800 for its print edition and ISSN 2277-4203 for its online edition, is a peer-reviewed journal dedicated exclusively to keratoconus, ectatic corneal diseases, and the full clinical spectrum of corneal ectasia management. Published by Jaypee Brothers Medical Publishers, one of India's most established medical publishing houses headquartered in New Delhi, India, the journal covers everything from corneal cross-linking protocols and collagen CXL outcomes to intrastromal corneal ring segments, anterior lamellar keratoplasty, deep anterior lamellar keratoplasty, femtosecond laser applications, and the diagnostic role of corneal topography and corneal biomechanics in clinical practice.

What makes IJKECD particularly interesting from an advertiser's perspective is its scope — it is not merely an Indian journal that happens to cover keratoconus; it positions itself as a global platform for the sub-specialty, which means its readership includes cornea specialists, refractive surgeons, and academic ophthalmologists who are actively engaged with the latest evidence on conditions like pellucid marginal degeneration, keratoglobus, post-LASIK ectasia, and Terrien's Marginal Degeneration. The journal operates on a continuous publication model, which is increasingly the standard for peer-reviewed titles that want to reduce the lag between acceptance and reader access. It is also preserved through Portico, the digital preservation service, which signals a level of institutional seriousness that advertisers should factor into their perception of the journal's longevity and credibility.

The journal is accessible through JaypeeDigital and indexed through several academic databases, and while its PubMed indexing status is something brands should verify directly with Jaypee Brothers Medical Publishers before making placement decisions, the journal's association with the Jaypee ecosystem — which includes dozens of indexed medical titles — lends it significant credibility in the Indian medical publishing landscape. It is also published under a Creative Commons License framework for its open access content, which means research articles are freely accessible to practitioners, potentially amplifying the reach of any advertisement placed alongside editorial content.

Who Reads IJKECD? Understanding the Journal's Target Audience in India

Frankly speaking, the readership profile of the International Journal of Keratoconus and Ectatic Corneal Diseases is one of the most tightly defined in Indian ophthalmology publishing — and that is precisely what makes it valuable for advertisers who are tired of paying for reach that does not convert. The primary readers are cornea specialists and subspecialty-trained ophthalmologists who manage keratoconus diagnosis and keratoconus treatment in India on a daily basis; these are clinicians who are making prescribing decisions and equipment procurement recommendations, not passive information consumers. India has somewhere in the range of 20,000 to 25,000 registered ophthalmologists, according to estimates cited by the All India Ophthalmological Society, but the subset that actively manages ectatic corneal diseases — and therefore represents the most relevant audience for IJKECD — is considerably smaller and considerably more influential in their institutional settings.

On top of that, the journal draws readership from refractive surgeons who encounter post-LASIK ectasia and need to stay current on excimer laser corneal surgery protocols and management pathways; from optometrists who fit contact lenses for keratoconus patients, which is a growing clinical practice in India's tier-one cities; and from academic researchers at institutions like L V Prasad Eye Institute, which is one of the most respected corneal disease centres in the country. This audience segmentation matters enormously when you are planning a media buy, because a pharmaceutical brand launching a new ophthalmic solution for corneal disease management has a very different targeting need than a medical device company promoting a corneal topography system — yet both audiences are present in IJKECD's readership in meaningful numbers.

What a lot of people miss is that journal readership in India is not purely print-based anymore; the open access model adopted by IJKECD means that practitioners in smaller cities — where print distribution may be slower — are accessing the journal digitally, which expands the effective journal readership India-wide beyond what traditional print circulation figures would suggest. At SmartAds, we always tell our clients that when you are evaluating a specialist publication like this, the question is not just how many people receive it, but how many of those people are the exact decision-maker your brand needs to reach — and on that metric, IJKECD performs exceptionally well for the corneal disease specialists India segment.

What Types of Advertisements Can You Place in IJKECD?

The range of advertising formats available in the International Journal of Keratoconus and Ectatic Corneal Diseases follows the standard Jaypee Brothers Medical Publishers inventory model, which is familiar to anyone who has placed advertisements in other Jaypee journals. For print, the primary formats include the full-page journal ad, which is the workhorse of medical journal advertising and offers the most visual real estate for product imagery, clinical data summaries, and brand messaging; the inside front cover ad, which commands a premium because it is the first page a reader encounters after opening the journal; and the back cover advertisement, which has consistently shown strong recall in readership studies across Indian medical journals because it is visible even when the journal is lying face-down on a desk.

Beyond those premium positions, half-page and quarter-page print advertisement options are typically available, which makes IJKECD accessible to brands with more modest budgets who still want the credibility of appearing in a peer-reviewed corneal disease journal. The thing is, we have seen smaller medical device companies — particularly those selling diagnostic instruments like corneal topography systems or slit-lamp accessories — use half-page placements very effectively because their message is technical and does not require the full canvas that a pharmaceutical brand might need for regulatory-compliant drug copy. For online advertisement options, the IJKECD website and the JaypeeDigital platform offer banner placements and sponsored content opportunities, though the specific inventory, dimensions, and pricing for digital formats should be confirmed directly with Jaypee Brothers at the time of booking, as digital ad products in Indian medical journals have been evolving rapidly.

One format category that is often overlooked in the ad booking process for specialist journals is the insert — a separately printed piece that is physically bound into the journal alongside the editorial content. Inserts allow for more complex creative executions, like fold-out clinical reference cards or product comparison sheets, which can be particularly effective for brands promoting equipment like femtosecond laser platforms or collagen CXL systems where technical specifications are a key part of the sales argument. Whether inserts are available in IJKECD specifically is something to confirm with Jaypee Brothers, but our experience shows that raising the question early in the booking conversation often opens up options that are not listed on a standard rate card.

How Do IJKECD's Print and Online Advertising Options Compare?

Print and online advertisement in the International Journal of Keratoconus and Ectatic Corneal Diseases serve genuinely different strategic purposes, which is why we rarely recommend one to the exclusion of the other for clients with sufficient budget. A print advertisement in a peer-reviewed journal carries a weight of institutional credibility that digital placements simply cannot replicate — when a corneal surgeon sees your brand's full-page journal ad in IJKECD, it is perceived as an endorsement of the journal's editorial environment, which is a high-trust context built over years of peer-reviewed content. This is particularly important for pharmaceutical advertising India, where prescriber trust is the ultimate currency, and for medical device advertising India, where clinical credibility can be the deciding factor in a capital equipment purchase.

Online advertisements on the IJKECD and JaypeeDigital platforms, on the other hand, offer measurability that print cannot match — click-through rates, impression counts, and geographic data on who is engaging with your creative. For a brand that is running a targeted campaign around keratoconus diagnosis India or keratoconus treatment India, a digital banner alongside a high-traffic article on corneal cross-linking CXL outcomes can deliver a very specific audience at a cost that is often lower than the equivalent print placement. The CPM for specialist medical journal digital placements in India works out to somewhere in the ballpark of what you would pay for a highly targeted LinkedIn campaign aimed at healthcare professionals, which is a number that tends to surprise clients who assume digital medical journal advertising is priced like premium display.

To be fair, the honest answer for most brands is that an integrated approach — combining a print advertisement in one or two issues with a sustained online advertisement presence across the publication year — delivers the best brand awareness ophthalmology outcomes. We worked with a pharmaceutical brand India ophthalmology client who had previously run only print ads in broader ophthalmology journals; when we shifted a portion of their budget to include digital placements in specialist journals alongside their print buys, their brand recall among cornea specialists India improved measurably in a post-campaign survey, which validated the multi-format strategy we had recommended.

What Are the Advertising Rates and Formats Available in IJKECD?

This is the question we get asked most often, and we will be honest: Jaypee Brothers Medical Publishers does not publish a publicly available rate card for IJKECD on their website, which means most advertisers are going in blind when they first approach the journal. Based on our experience with Jaypee journals advertisement bookings and comparable specialist medical journal advertising in India, a full-page journal ad in a title like IJKECD would typically be priced somewhere between ₹30,000 and ₹60,000 per insertion, depending on position and issue — with premium positions like the inside front cover ad and back cover advertisement commanding a premium of roughly 40 to 60 percent above the standard full-page rate. These are indicative figures, and the actual medical journal ad rates India for IJKECD should be confirmed directly with Jaypee Brothers, as rates are subject to revision and negotiation based on frequency commitments.

For context, the Indian Journal of Ophthalmology — which is a much higher-circulation title published by the All India Ophthalmological Society — commands significantly higher rates for equivalent positions, with full-page rates that can run considerably above what a specialist journal like IJKECD would charge. This is actually an argument in IJKECD's favour for advertisers with a specific corneal disease focus: the cost per relevant impression is almost certainly lower in IJKECD than in a broader ophthalmology journal, because you are not paying for reach to general ophthalmologists who may never encounter a keratoconus patient in their practice. At SmartAds, we frame this to our clients as the difference between buying a large audience and buying the right audience — and for niche pharmaceutical and device categories, the right audience wins every time.

For artwork specifications, print advertisements in Jaypee journals are typically required in high-resolution PDF format at 300 DPI, with dimensions conforming to the journal's trim size; the standard full-page ad dimension for most Jaypee titles is in the range of 210 mm x 280 mm, though this should be confirmed with the production team at the time of booking. GST at 18 percent is applicable on advertising services in India, which is a line item that sometimes catches first-time medical journal advertisers off guard when they receive their invoice — so it is worth factoring into budget planning from the outset. Payment terms for Jaypee Brothers ad bookings are generally advance payment or payment against invoice, and the advertisement submission deadline is typically four to six weeks before the issue publication date, though this can vary.

How Do You Submit an Advertisement to IJKECD via Jaypee Brothers?

The ad booking process for the International Journal of Keratoconus and Ectatic Corneal Diseases runs through Jaypee Brothers Medical Publishers' advertising team in New Delhi, India, and the primary contact for Jaypee journals advertisement enquiries is Sanjeev Kumar, whose details are available through the Jaypee Brothers corporate website and the JaypeeDigital platform. The process is more straightforward than many first-time medical journal advertisers expect — it begins with an initial enquiry to confirm available positions and issue dates, followed by a rate discussion, a formal booking confirmation, and then the submission of print-ready artwork before the advertisement submission deadline.

What we tell our clients is to initiate the booking conversation at least eight to ten weeks before the issue in which they want to appear, because premium positions like the inside front cover ad and back cover advertisement are limited inventory and tend to be committed early, particularly for issues that coincide with major ophthalmology conferences or events where journal visibility spikes. The All India Ophthalmological Society annual conference, for example, is a period when journal readership among ophthalmologists India is demonstrably higher, and advertisers who plan their IJKECD placements around such moments tend to see better engagement with their creative. On top of that, if your brand is running a campaign that combines print advertisement in IJKECD with digital placements on JaypeeDigital, coordinating both bookings through a single agency contact simplifies the workflow considerably.

For pharmaceutical brands, the artwork submission process carries an additional compliance layer — drug advertisements must include approved prescribing information, and the creative must have cleared internal medical-legal review before it is submitted to the journal. We have seen this backfire when brands submit artwork before their regulatory review is complete and then miss the advertisement submission deadline because internal approvals took longer than expected; the solution is to build regulatory review time into your campaign timeline from day one, not as an afterthought. Jaypee Brothers' production team is generally responsive and professional, but they cannot hold premium positions indefinitely while a brand's internal processes catch up.

What Are IJKECD's Advertising Policies and Compliance Requirements?

The advertising policy compliance framework for the International Journal of Keratoconus and Ectatic Corneal Diseases reflects the broader standards that apply to pharmaceutical advertising India across all peer-reviewed medical journals — and these are standards that brands sometimes underestimate until they encounter a rejection or a request for revision. The journal, as a peer-reviewed publication with editorial independence, maintains a clear separation between its advertising content and its editorial content; this means that no advertisement can be designed to resemble an editorial article, and no advertiser relationship can influence the journal's peer-review process or publication decisions. This editorial independence is not just an ethical principle — it is what gives the journal its credibility, and by extension, what gives your advertisement its credibility by association.

For pharmaceutical drug advertisements specifically, the applicable compliance framework in India is governed by the CDSCO and DCGI guidelines, as well as the WHO drug advertisement criteria, which require that drug advertisements in medical journals include accurate prescribing information, approved indications, contraindications, and safety data. The creative cannot make claims that go beyond what is approved in the product's regulatory dossier, and any clinical data cited in the advertisement must be from published, peer-reviewed sources — which is actually a natural fit for IJKECD, given that its own editorial content frequently publishes the kind of clinical outcome data that pharmaceutical brands want to reference. Brands that are new to pharmaceutical advertising India sometimes find this compliance framework restrictive, but experienced healthcare marketers understand that it is precisely this rigour that makes medical journal advertising credible to the prescriber audience.

For medical device companies, the compliance requirements are somewhat different — device advertisements in Indian medical journals are governed by the Medical Devices Rules under the Drugs and Cosmetics Act, and claims about diagnostic accuracy, clinical outcomes, or comparative performance must be substantiated. A company advertising a corneal topography system, for example, cannot make unsubstantiated claims about diagnostic superiority without published evidence to back them up; similarly, a brand promoting femtosecond laser platforms for corneal cross-linking CXL or intrastromal corneal ring segments implantation would need to ensure that any clinical claims in their creative are evidence-based. At SmartAds, we work with our healthcare clients' regulatory teams to ensure that ad copy is both compelling and compliant before it ever reaches a journal's production desk.

Why Is India a Key Market for Keratoconus and Corneal Disease Advertising?

The scale of the keratoconus and corneal disease burden in India is something that most general advertisers are not aware of — and it represents a significant commercial opportunity for brands in the right categories. Keratoconus prevalence India is estimated to be higher than the global average, with some studies suggesting a prevalence of roughly 1 in 2,000 in the general population, though the actual burden may be higher given the historically low rates of keratoconus diagnosis India in rural and semi-urban settings. Corneal blindness India is one of the leading causes of preventable vision loss in the country, which has driven significant investment in corneal disease infrastructure — from dedicated cornea clinics at tertiary centres to the expansion of corneal cross-linking services at secondary hospitals — and this infrastructure growth directly expands the addressable market for brands in this space.

The India ophthalmology market has been growing at a rate that consistently outpaces the broader healthcare sector, driven by increasing awareness, rising surgical volumes, and the expansion of eye care networks into tier-two and tier-three cities. Keratoconus treatment India has seen particular growth in the adoption of collagen cross-linking CXL as a standard of care for progressive keratoconus, which has created a substantial and growing market for the riboflavin solutions, UV-A devices, and diagnostic tools that support the procedure. On top of that, the growing adoption of contact lens for keratoconus management — particularly scleral lenses and rigid gas-permeable designs — has expanded the relevant audience beyond surgeons to include optometrists and contact lens practitioners, all of whom are potential readers of IJKECD and potential targets for brands in the vision correction and contact lens space.

One automotive brand analogy we often use with clients is this: advertising corneal disease products in a broad ophthalmology journal is like advertising a performance car in a general lifestyle magazine — you will reach some of the right people, but you will pay for a lot of irrelevant impressions. Advertising in IJKECD is like placing that same ad in a specialist motoring publication where every reader is already in the market. The India ophthalmology market is large enough that broad-reach strategies have their place, but for categories like corneal cross-linking equipment, deep anterior lamellar keratoplasty surgical instruments, or pharmaceutical products for ectatic corneal diseases management, the specialist journal route delivers a quality of audience that broad media simply cannot match.

How Does IJKECD Compare to the Indian Journal of Ophthalmology for Advertising?

This is a comparison we get asked about regularly, and the honest answer is that they serve different strategic purposes rather than one being straightforwardly better than the other for advertise in medical journal India decisions. The Indian Journal of Ophthalmology, published by the All India Ophthalmological Society and distributed to its membership of tens of thousands of ophthalmologists across India, offers significantly higher medical journal circulation India figures — making it the right choice for brands that need broad reach across the entire ophthalmology specialty, such as a pharmaceutical company launching a new topical antibiotic or an equipment manufacturer promoting a general-purpose slit lamp. The IJO's reach is its primary selling point, and its advertising rates reflect that premium accordingly.

The International Journal of Keratoconus and Ectatic Corneal Diseases, by contrast, delivers depth over breadth — its targeted audience ophthalmology profile is concentrated among cornea subspecialists, refractive surgeons, and researchers who are specifically engaged with ectatic corneal diseases, which means that every impression is a high-value one for brands in the relevant categories. From a cost-efficiency standpoint, the cost per relevant reader in IJKECD is likely to be considerably lower than in the IJO for a brand whose product is specifically indicated for keratoconus or corneal ectasia management; this is a nuance that media planners who are accustomed to thinking in terms of raw circulation numbers sometimes miss. We have found, in our experience at SmartAds, that the brands which get the best ROI from ophthalmology journal advertising are those that match their journal selection to their precise target prescriber profile rather than defaulting to the highest-circulation title.

Highlights of Ophthalmology is another title that sometimes enters this comparison, particularly for international brands looking at the Latin American and Indian markets simultaneously; it has a different editorial focus and distribution model than IJKECD, and the two are not really competing for the same readership. For a brand specifically focused on corneal disease specialists India, IJKECD's specialisation is a genuine differentiator — there is no other peer-reviewed journal in India, and arguably very few globally, that is as tightly focused on the keratoconus and ectatic corneal diseases spectrum, which means that a brand appearing in its pages is reaching a readership that has self-selected for interest in exactly the clinical area the brand operates in.

What Brands and Products Benefit Most from Advertising in IJKECD?

The categories that get the most value from magazine advertising in the International Journal of Keratoconus and Ectatic Corneal Diseases are, perhaps unsurprisingly, those whose products are directly implicated in the diagnosis and management of keratoconus and ectatic corneal diseases — but the list is broader than most brands initially assume. The most obvious candidates are pharmaceutical brands India ophthalmology with products used in corneal cross-linking protocols, including the riboflavin eye drops that are central to the collagen cross-linking CXL procedure; these brands benefit from appearing in a journal that their exact prescribers are reading for clinical updates on the very procedure their product supports. Similarly, companies manufacturing UV-A irradiation devices for CXL, corneal topography systems for keratoconus diagnosis India, and femtosecond laser platforms used in procedures like intrastromal corneal ring segments implantation and deep anterior lamellar keratoplasty are natural fits for IJKECD magazine advertising.

Beyond the surgical and diagnostic equipment categories, there is a meaningful opportunity for contact lens manufacturers — particularly those with products specifically designed for contact lens for keratoconus management, such as scleral lenses, mini-scleral designs, and custom rigid gas-permeable lenses — to reach both the prescribing ophthalmologists and the optometrists who fit these lenses in clinical practice. This is a segment of the India ophthalmology market that is growing rapidly as awareness of keratoconus diagnosis India improves and more patients are identified earlier in the disease course, when optical correction with specialist contact lenses is still the primary management approach. We worked with a contact lens brand that had previously focused almost entirely on digital advertising to reach optometrists; when we introduced a print advertisement strategy in specialist ophthalmology journals alongside their existing digital spend, their brand awareness among cornea specialists India — who are the referring physicians for complex keratoconus contact lens fits — improved substantially within two issue cycles.

Pharmaceutical advertising India in IJKECD also extends to brands whose products address the comorbidities and complications associated with ectatic corneal diseases — including dry eye therapies, anti-allergy ophthalmic solutions (since allergic eye disease is a known risk factor for keratoconus progression), and post-operative care products used after anterior lamellar keratoplasty or excimer laser corneal surgery. Healthcare marketing India for these adjacent categories benefits from the specialist context that IJKECD provides; a dry eye brand appearing in a keratoconus journal is not off-topic — it is speaking to clinicians who manage these patients holistically and are receptive to information about the full spectrum of care.

FAQ: Advertising in the International Journal of Keratoconus and Ectatic Corneal Diseases

Q: How can I advertise in the International Journal of Keratoconus and Ectatic Corneal Diseases?

The ad booking process for IJKECD runs through Jaypee Brothers Medical Publishers in New Delhi, India; the advertising contact is Sanjeev Kumar, whose details are available through the Jaypee Brothers website and the JaypeeDigital platform. The process involves an initial enquiry to discuss available positions and issue dates, followed by rate negotiation, a formal booking confirmation, and submission of print-ready artwork before the advertisement submission deadline. For brands that are new to Jaypee journals advertisement bookings, working through an experienced media agency like SmartAds can simplify the process considerably, particularly if you are coordinating placements across multiple Jaypee titles or combining print and online advertisement formats.

Q: What are the advertising rates and formats available in IJKECD?

Jaypee Brothers does not publish a public rate card for IJKECD, which means rates must be obtained directly through enquiry. Based on our experience with comparable specialist medical journals in India, a full-page journal ad would typically be priced somewhere in the range of ₹30,000 to ₹60,000 per insertion, with the inside front cover ad and back cover advertisement commanding a premium of roughly 40 to 60 percent above the standard rate. Half-page and quarter-page formats are generally available at proportionally lower rates. All rates are subject to GST at 18 percent, and frequency discounts are typically available for brands committing to multiple insertions across a publication year. Online advertisement rates on the JaypeeDigital platform are separate and should be discussed alongside print options for an integrated campaign.

Q: What is the readership and circulation of IJKECD in India?

IJKECD's precise medical journal circulation India figures are not publicly disclosed, which is common for specialist academic journals in India. The journal's readership is concentrated among cornea specialists, refractive surgeons, and academic ophthalmologists in India and internationally; given its open access model and digital availability through JaypeeDigital, the effective journal readership India extends well beyond physical print distribution. The journal's continuous publication model also means that individual articles — and any advertisements appearing alongside them — are accessible online as soon as they are published, rather than waiting for a quarterly or biannual print run.

Q: Who is the publisher of IJKECD and how do I contact them for advertising?

The International Journal of Keratoconus and Ectatic Corneal Diseases is published by Jaypee Brothers Medical Publishers, one of India's largest and most established medical publishing houses, headquartered in New Delhi, India. For advertising enquiries, Sanjeev Kumar is the named advertising contact for Jaypee journals, and he can be reached through the Jaypee Brothers corporate website. The JaypeeDigital platform also provides contact information for both print and online advertisement enquiries.

Q: Does IJKECD accept online or digital advertisements in addition to print ads?

Yes — the JaypeeDigital platform, which hosts IJKECD's online content, offers digital advertising options including banner placements and potentially sponsored content formats. The specific inventory, dimensions, and pricing for online advertisement in IJKECD should be confirmed with Jaypee Brothers at the time of booking, as digital ad products are evolving. For brands that want to reach the journal's readership between print issues or target the growing segment of practitioners who access IJKECD digitally, online advertisement is a valuable complement to print placements.

Q: What types of products and brands are suitable for advertising in IJKECD?

The most relevant categories for IJKECD magazine advertising include pharmaceutical brands with products used in corneal cross-linking CXL protocols, medical device companies manufacturing corneal topography systems, femtosecond laser platforms, and intrastromal corneal ring segments implantation instruments, contact lens manufacturers with products for keratoconus management, and surgical instrument companies serving the anterior lamellar keratoplasty and deep anterior lamellar keratoplasty markets. Adjacent categories — including dry eye therapies, anti-allergy ophthalmic solutions, and post-operative care products — also find a receptive audience among IJKECD's corneal disease specialists India readership.

Q: What compliance rules apply to pharmaceutical advertisements in IJKECD?

Pharmaceutical advertising in IJKECD must comply with CDSCO and DCGI guidelines under India's Drugs and Cosmetics Act, as well as the WHO drug advertisement criteria, which require that drug advertisements include accurate prescribing information, approved indications, contraindications, and safety data. The journal maintains editorial independence, which means advertising content must be clearly distinguished from editorial content and cannot make claims that exceed the product's approved regulatory dossier. Medical device advertising India is governed by the Medical Devices Rules, which require that performance claims be substantiated by published evidence. Advertising policy compliance is a non-negotiable aspect of medical journal advertising in India, and brands should ensure their creative has cleared internal medical-legal review before submission.

Q: How far in advance must I submit my advertisement material for IJKECD?

The advertisement submission deadline for IJKECD is typically four to six weeks before the issue publication date, though this can vary and should be confirmed with Jaypee Brothers at the time of booking. For premium positions like the inside front cover ad and back cover advertisement, we recommend initiating the booking conversation at least eight to ten weeks in advance, as these positions are limited and tend to be committed early. Pharmaceutical brands should factor in additional time for internal medical-legal review of their creative, which can add two to four weeks to the pre-submission timeline.

Q: How does IJKECD's advertising reach compare to broader ophthalmology journals like the Indian Journal of Ophthalmology?

The Indian Journal of Ophthalmology has significantly higher medical journal circulation India figures and reaches a broader audience of general ophthalmologists across India, making it the right choice for mass-reach campaigns within the ophthalmology specialty. IJKECD's strength is its targeted audience ophthalmology profile — it reaches cornea subspecialists and researchers who are specifically engaged with ectatic corneal diseases, which means the cost per relevant impression for brands in the corneal disease space is likely to be considerably lower in IJKECD than in the IJO. For brands with a specific keratoconus or corneal ectasia focus, the two journals are complementary rather than competitive, and an integrated strategy using both can deliver both depth and breadth.

Q: Is IJKECD indexed on PubMed, and does that affect the value of advertising in it?

PubMed indexing is a significant credibility signal for any peer-reviewed journal, as it indicates that the journal meets the National Library of Medicine's standards for scientific quality and editorial rigour. Brands should verify IJKECD's current indexing status directly with Jaypee Brothers, as indexing status can change. What is clear is that the journal's association with the Jaypee Brothers ecosystem, its ISSN registrations (ISSN 2277-3800 for print and ISSN 2277-4203 online), and its Portico digital preservation status all signal institutional seriousness; a journal that is taken seriously by the academic community is one whose advertising environment is taken seriously by the prescriber audience.

Q: What is the publication frequency of IJKECD and how does it affect ad scheduling?

IJKECD operates on a continuous publication model, which means articles are published online as they are accepted rather than being held for a scheduled issue date. For advertisers, this means that the traditional quarterly or biannual issue-based scheduling model may be supplemented by ongoing digital visibility through the JaypeeDigital platform. Print editions are typically produced on a defined schedule, and ad scheduling should be coordinated with Jaypee Brothers to ensure placements align with print production timelines and any high-visibility periods such as major ophthalmology conference seasons.

Q: Can a medical device company advertise diagnostic tools like corneal topography systems in IJKECD?

Absolutely — in fact, corneal topography systems are among the most natural product categories for IJKECD magazine advertising, given that corneal topography and corneal biomechanics assessment are central to keratoconus diagnosis India and the monitoring of ectatic corneal diseases progression. Medical device advertising India in IJKECD must comply with the Medical Devices Rules, and any clinical performance claims must be substantiated by published evidence. Companies promoting diagnostic platforms, femtosecond laser systems, or instruments used in anterior lamellar keratoplasty and deep anterior lamellar keratoplasty procedures will find a highly receptive and technically sophisticated audience in IJKECD's readership.

Placing Your Brand in the Right Hands: A Closing Perspective

There is a version of media planning that treats every publication as interchangeable — a CPM is a CPM, a page is a page, and the cheapest reach wins. We have never subscribed to that view at SmartAds, and nowhere is that philosophy more clearly vindicated than in specialist medical journal advertising. The International Journal of Keratoconus and Ectatic Corneal Diseases represents something genuinely rare in Indian medical publishing: a peer-reviewed journal with a precisely defined editorial scope that maps almost perfectly onto a growing, commercially significant clinical subspecialty. The brands that recognise this early — before the advertising inventory becomes competitive and rates reflect that competition — are the ones that will build durable brand awareness among corneal disease specialists India over the next decade.

The keratoconus and ectatic corneal diseases market in India is at an inflection point; rising awareness of keratoconus diagnosis India, expanding access to corneal cross-linking CXL services, and the growing adoption of advanced surgical techniques like deep anterior lamellar keratoplasty and femtosecond laser-assisted procedures are all driving an increase in the number of active prescribers and decision-makers in this space. Pharmaceutical advertising India and medical device advertising India in this category are both growing, which means the audience that IJKECD delivers is not static — it is expanding as the subspecialty itself expands. A brand that establishes consistent visibility in IJKECD now is building equity with a readership that will only become more valuable over time.

Our experience at SmartA